ENSG vs ORKA
Ensign Group vs Oruka Therapeutics, Inc. — AI-powered side-by-side comparison
VS
ORKA
Oruka Therapeutics, Inc.
59
Watch
| Metric | ENSG | ORKA |
|---|
| AI Score |
69
|
59
|
| Price |
$180.10
|
$104.56
|
| P/E Ratio |
27.43×
|
-43.80×
|
| ROE |
15.4%
|
-22.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
14.1%
|
0.0%
|
| Debt / Equity |
0.92×
|
0.00×
|
| Dividend Yield |
0.1%
|
0.0%
|
| RSI (14) |
71.8
|
74.0
|
| Beta |
0.694
|
-0.389
|
| Expected Upside |
+5.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ENSG versus ORKA.
ENSG leads by 10 points.
ENSG scores 69/100 (Buy) versus ORKA at 59/100 (Watch).
ENSG Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- RSI at 72 is in overbought territory — Technical
ORKA Committee View
60% agreement
5 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -26.0% -- cheap may mean cheap for a reason — Value
- RSI at 74 is in overbought territory — Technical
- Weekly RSI at 86 -- overbought on the larger timeframe too — Technical